Cable Car Capital’s Gain Therapeutics GANX Stock Holding History

Cable Car Capital’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-145,000	Closed	-$186K	–	65
2024 Q2	$186K	Buy	+145,000	New	+$376K	0.2%	39

Other funds holding GANX

GAM

Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cable Car Capital's GANX Position: Q3 2024 in Review

Cable Car Capital sold out of Gain Therapeutics (GANX) in Q3 2024, closing a stake of 145,000 shares — an estimated $186K sold.

Cable Car Capital first reported a position in GANX in Q2 2024 and held it in 1 quarter. The position peaked at $186K in Q2 2024. 19 funds tracked by Wall St. Rank hold GANX as of Q3 2024.

Cable Car Capital reported no remaining Gain Therapeutics position as of Q3 2024 after selling out during the quarter.
Cable Car Capital sold 145,000 Gain Therapeutics shares in Q3 2024, an estimated $186K.
Cable Car Capital first reported a position in Gain Therapeutics in Q2 2024 and held it in 1 quarter.
Cable Car Capital's Gain Therapeutics position peaked at $186K in Q2 2024.
19 funds tracked by Wall St. Rank held Gain Therapeutics as of Q3 2024.

Based on Cable Car Capital's 13F filing for Q3 2024, filed 14 Nov 2024.